NAMSNewAmsterdam Pharma Company NV

Pictet Asset Management Holding SA trimmed its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 42.3% in the 4th quarter, according to the company in its most...

Jennison Associates LLC trimmed its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 16.9% during the 4th quarter, according to the company in its most recent...

NewAmsterdam Pharma (NASDAQ:NAMS) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

Moody Aldrich Partners LLC bought a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 143,549 shares of the company's stock, valued at approximately...

NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 8% - Should You Sell...

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twelve analysts that are currently covering the company...

Aberdeen Group plc grew its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 10.2% during the fourth quarter, according to its most recent disclosure with the Securities...

JPMorgan Chase & Co. cut its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 10.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,302,498 shares of the company's stock after sell...

Truist Financial assumed coverage on NewAmsterdam Pharma in a research report on Wednesday. They set a "buy" rating and a $57.00 price target on the stock...